Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 8/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beminafil SCHEMBL29385559 | 0.92 | PDE5A (0.47) | PDE5APDE11A | |
| Beminafil SCHEMBL2421274 | 0.92 | PDE5A (0.47) | PDE5APDE11A | |
| Beminafil SCHEMBL2421268 | 0.92 | PDE5A (0.47) | PDE5APDE11A | |
| Bicarbonate SCHEMBL6216777 | 0.92 | PDE5A (0.42) | PDE5APDE10APOLBKMT2A | |
| Beminafil SCHEMBL6236544 | 0.92 | PDE5A (0.46) | PDE5APDE11A | |
| SCHEMBL7680595 | 0.91 | PDE5A (0.36) | PDE5APDE10APOLBKMT2AALDH1A1 | |
| SCHEMBL6764887 | 0.90 | MEN1 (0.40) | PDE5APDE10AKMT2AALDH1A1 | |
| SCHEMBL6764615 | 0.89 | PDE10A (0.40) | PDE5APDE10APOLBALDH1A1 | |
| Beminafil SCHEMBL7124593 | 0.88 | PDE5A (0.44) | PDE5APDE11A | |
| Beminafil SCHEMBL29419601 | 0.88 | PDE5A (0.44) | PDE5APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030022906-A1 | Use of pde v inhibitors | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| US-6495557-B1 | SUCH AS 3-(4-(3-CHLORO-4-METHOXYBENZYLAMINO)BENZO-(4,5)-THIENO (2,3-D)PYRIMIDIN-2-YL)PROPIONIC ACID; CARDIOVASCULAR DISORDERS AND/OR IMPAIRED POTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PDE5A 9/4885PDE10A 69/4885PDE11A 28/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | PDE5A 7/4885PDE10A 99/4885PDE11A 44/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | PDE5A 261/4885PDE10A 924/4885PDE11A 713/4885 |
| US-20030022906-A1 | Use of pde v inhibitors | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE10A 9/4885PDE11A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.